References
- Beral V, Bull D, Reeves G. 2005. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365:1543–1551.
- Fallat M, Donahoe P. 2006. Intersex genetic anomalies with malignant potential. Current Opinion in Pediatrics 18:305–311.
- Gidwani GP, Seiler JC, Ballard LA Jr. 1979. Turner's syndrome: results of estrogen therapy. Cleveland Clinic Quarterly 46:19–22.
- Heinz M. 2010. Hormonal development therapy (HDT) in hypogonadism in long-term view. Best Practice and Research: Clinical Obstetrics and Gynaecology 24:149–155.
- Krishnamurthy S, Adcock LL, Okagaki T. 1977. Endometrial carcinoma following estrogen-progestagen therapy in Turner's syndrome: a case report and review of the literature. Gynecologic Oncology 5:291–298.
- Matsui H, Ishii J, Onodera T et al. 1997. Endometrial carcinoma in 45,X Turner's syndrome without hormone replacement therapy. Gynecologic Oncology 65:548–552.
- McCarroll AM, Montgomery DA, Harley JM et al. 1975. Endometrial carcinoma after cyclical oestrogen-progestagen therapy for Turner's syndrome. British Journal of Obstetrics and Gynaecology 82:421–423.
- Michala L, Goswami D, Creighton S et al. 2008. Swyer syndrome: presentation and outcomes. British Journal of Obstetrics and Gynaecology 115: 737–741.
- Roberts G, Wells AL. 1975. Oestrogen-induced endometrial carcinoma in a patient with gonadal dysgenesis. British Journal of Obstetrics and Gynaecology 82:417–420.
- Wilkinson EJ, Friedrich EG Jr, Mattingly RF et al. 1973. Turner's syndrome with endometrial adenocarcinoma and stilbestrol therapy. Obstetrics and Gynecology 42:193–200.